Eloxx Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	6.36	4.79	0.11	1.13	19.21	42.27
Cash & Short-Term Investments	6.36	4.79	0.11	1.13	19.21	42.27
Cash Growth	5632.43%	4210.81%	-90.21%	-94.10%	-54.56%	71.35%
Accounts Receivable	-	-	2.72	-	-	-
Other Current Assets	2.14	0.49	0.15	0.41	0.92	1.21
Total Current Assets	8.5	5.27	2.98	1.55	20.13	43.48
Net Property, Plant & Equipment	-	-	-	0.16	0.99	1.66
Total Assets	8.5	5.27	2.98	1.71	21.12	45.14
Accounts Payable	3.03	2.71	5.35	5.7	3.02	1.38
Accrued Expenses	1.24	1.65	2	1.21	2.8	4.2
Current Portion of Long-Term Debt	-	1	6.52	2.22	3.98	-
Current Portion of Leases	-	-	0	0.13	0.71	0.66
Unearned Revenue	11.82	11.82	13.35	12.97	12.54	3.72
Other Current Liabilities	-	-	0.1	0.47	0.05	-
Total Current Liabilities	16.09	17.18	27.31	22.7	23.09	9.96
Long-Term Debt	-	-	-	1.61	8.56	12
Long-Term Leases	-	-	-	0	0.14	0.8
Total Long-Term Liabilities	-	-	-	1.61	8.69	12.8
Total Liabilities	16.09	17.18	27.31	24.31	31.78	22.76
Common Stock	0.05	0.05	0.04	0.03	0.02	0.02
Treasury Stock	-	-	-	-	-	-2.19
Additional Paid-in Capital	296.7	288.63	270.22	268.81	263.71	262.88
Retained Earnings	-304.33	-300.58	-294.59	-291.44	-274.39	-238.32
Shareholders' Equity	-7.58	-11.91	-24.34	-22.6	-10.66	22.38
Total Liabilities & Equity	8.5	5.27	2.98	1.71	21.12	45.14